727 related articles for article (PubMed ID: 20214408)
1. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
2. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
5. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
6. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
7. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
8. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
[TBL] [Abstract][Full Text] [Related]
9. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
10. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
Han B; Mao J; Chien JY; Hall SD
Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
16. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
17. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Ling SY; Huizinga RB; Mayo PR; Larouche R; Freitag DG; Aspeslet LJ; Foster RT
Br J Clin Pharmacol; 2014 Jun; 77(6):1039-50. PubMed ID: 24330024
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
